248 related articles for article (PubMed ID: 10464888)
1. Inhaled beclomethasone (BDP) with non-CFC propellant (HFA 134a) is equivalent to BDP-CFC for the treatment of asthma.
Milanowski J; Qualtrough J; Perrin VL
Respir Med; 1999 Apr; 93(4):245-51. PubMed ID: 10464888
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic equivalence of inhaled beclomethasone dipropionate with CFC and non-CFC (HFA 134a) propellants both delivered via the Easibreathe inhaler for the treatment of paediatric asthma.
Farmer IS; Middle M; Savic J; Perri VL; Herdman MJ
Respir Med; 2000 Jan; 94(1):57-63. PubMed ID: 10714480
[TBL] [Abstract][Full Text] [Related]
3. Effects on lung function, symptoms, and bronchial hyperreactivity of low-dose inhaled beclomethasone dipropionate given with HFA-134a or CFC propellant.
Woodcock A; Williams A; Batty L; Masterson C; Rossetti A; Cantini L
J Aerosol Med; 2002; 15(4):407-14. PubMed ID: 12581507
[TBL] [Abstract][Full Text] [Related]
4. Equivalence of asthma control with new CFC-free formulation HFA-134a beclomethasone dipropionate and CFC-beclomethasone dipropionate.
Dahl R; Ringdal N; Ward SM; Stampone P; Donnell D
Br J Clin Pract; 1997; 51(1):11-5. PubMed ID: 9158265
[TBL] [Abstract][Full Text] [Related]
5. A new HFA-134a propellant in the administration of inhaled BDP via the Jet spacer: controlled clinical trial vs the conventional CFC.
Vondra V; Sladek K; Kotasová J; Terl M; Rossetti A; Cantini L
Respir Med; 2002 Oct; 96(10):784-9. PubMed ID: 12412977
[TBL] [Abstract][Full Text] [Related]
6. Long-term safety and efficacy of a chlorofluorocarbon-free beclomethasone dipropionate extrafine aerosol.
Fireman P; Prenner BM; Vincken W; Demedts M; Mol SJ; Cohen RM
Ann Allergy Asthma Immunol; 2001 May; 86(5):557-65. PubMed ID: 11379808
[TBL] [Abstract][Full Text] [Related]
7. Hydrofluoroalkane-134a beclomethasone dipropionate extrafine aerosol provides equivalent asthma control to chlorofluorocarbon beclomethasone dipropionate at approximately half the total daily dose.
Davies RJ; Stampone P; O'Connor BJ
Respir Med; 1998 Jun; 92 Suppl A():23-31. PubMed ID: 9850360
[TBL] [Abstract][Full Text] [Related]
8. Efficacy response of inhaled beclomethasone dipropionate in asthma is proportional to dose and is improved by formulation with a new propellant.
Busse WW; Brazinsky S; Jacobson K; Stricker W; Schmitt K; Vanden Burgt J; Donnell D; Hannon S; Colice GL
J Allergy Clin Immunol; 1999 Dec; 104(6):1215-22. PubMed ID: 10589004
[TBL] [Abstract][Full Text] [Related]
9. Clinical efficacy and safety of fluticasone propionate 1 mg twice daily administered via a HFA 134a pressurized metered dose inhaler to patients with severe asthma. U.K. study group.
Ayres JG; Millar AB; Sykes AP
Respir Med; 2000 Jun; 94 Suppl B():S42-50. PubMed ID: 10919685
[TBL] [Abstract][Full Text] [Related]
10. Switch to non-CFC inhaled corticosteroids: a comparative efficacy study of HFA-BDP and CFC-BDP metered-dose inhalers.
Demedts M; Cohen R; Hawkinson R
Int J Clin Pract; 1999; 53(5):331-8. PubMed ID: 10695095
[TBL] [Abstract][Full Text] [Related]
11. Safety of hydrofluoroalkane-134a beclomethasone dipropionate extrafine aerosol.
Thompson PJ; Davies RJ; Young WF; Grossman AB; Donnell D
Respir Med; 1998 Jun; 92 Suppl A():33-9. PubMed ID: 9850361
[TBL] [Abstract][Full Text] [Related]
12. Hydrofluoroalkane-134a beclomethasone dipropionate, 400 microg, is as effective as chlorofluorocarbon beclomethasone dipropionate, 800 microg, for the treatment of moderate asthma.
Gross G; Thompson PJ; Chervinsky P; Vanden Burgt J
Chest; 1999 Feb; 115(2):343-51. PubMed ID: 10027430
[TBL] [Abstract][Full Text] [Related]
13. Acute safety of beclomethasone dipropionate in a new CFC-free propellant system in asthmatic patients.
Ayres JG; Simmons JL; Stampone P
Respir Med; 1999 Jan; 93(1):27-32. PubMed ID: 10464845
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of HFA-beclomethasone dipropionate extra-fine aerosol (800 microg day(-1)) versus HFA-fluticasone propionate (1000 microg day(-1)) in patients with asthma.
Aubier M; Wettenger R; Gans SJ
Respir Med; 2001 Mar; 95(3):212-20. PubMed ID: 11266239
[TBL] [Abstract][Full Text] [Related]
15. Short-term growth and adrenal function in children with asthma treated with inhaled beclomethasone dipropionate hydrofluoroalkane-134a.
Wolthers OD
Pediatr Allergy Immunol; 2006 Dec; 17(8):613-9. PubMed ID: 17121590
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of HFA-134a beclomethasone dipropionate extra-fine aerosol over six months.
Boulet LP; Cartier A; Ernst P; Larivée P; Laviolette M
Can Respir J; 2004 Mar; 11(2):123-30. PubMed ID: 15045043
[TBL] [Abstract][Full Text] [Related]
17. Switching from conventional to extrafine aerosol beclomethasone dipropionate therapy in children: a 6-month, open- label, randomized trial.
Szefler SJ; Warner J; Staab D; Wahn U; Le Bourgeois M; van Essen-Zandvliet EE; Arora S; Pedersen S;
J Allergy Clin Immunol; 2002 Jul; 110(1):45-50. PubMed ID: 12110818
[TBL] [Abstract][Full Text] [Related]
18. Short-term lower leg growth in 5- to 11-year-old asthmatic children using beclomethasone dipropionate inhalers with chlorofluorocarbon or hydrofluoroalkane propellants: a 9-week, open-label, randomized, crossover, noninferiority study.
Wolthers OD; Walters EG
Clin Ther; 2011 Aug; 33(8):1069-76. PubMed ID: 21784529
[TBL] [Abstract][Full Text] [Related]
19. Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone.
Leach CL; Davidson PJ; Boudreau RJ
Eur Respir J; 1998 Dec; 12(6):1346-53. PubMed ID: 9877489
[TBL] [Abstract][Full Text] [Related]
20. Growth, systemic safety, and efficacy during 1 year of asthma treatment with different beclomethasone dipropionate formulations: an open-label, randomized comparison of extrafine and conventional aerosols in children.
Pedersen S; Warner J; Wahn U; Staab D; Le Bourgeois M; Van Essen-Zandvliet E; Arora S; Szefler SJ;
Pediatrics; 2002 Jun; 109(6):e92. PubMed ID: 12042586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
